Published in final edited form as:

Biochem Biophys Res Commun. 2010 March 26; 394(1): 194–199. doi:10.1016/j.bbrc.2010.02.151.

High-Throughput Screening based Identification of Small Molecule Antagonists of Integrin CD11b/CD18 Ligand Binding

Mohd Hafeez Faridi¹, Dony Maignel¹, Brock T. Brown², Eigo Suyama², Constantinos J. Barth¹, Michael Hedrick², Stefan Vasile², Eduard Sergienko², Stephan Schürer^{3,*}, and Vineet Gupta^{1,4,*}

¹Peggy and Harold Katz Family Drug Discovery Center, Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miami, FL 33136

²Burnham Center for Chemical Genomics, Burnham Institute for Medical Research, 10901 North Torrey Pines Rd., La Jolla, CA 92037

³Department of Pharmacology and Center for Computational Science, University of Miami, Miami, FL 33176

⁴Department of Biochemistry and Molecular Biology, University of Miami, Miami, FL 33136.

Abstract

Binding of leukocyte specific integrin CD11b/CD18 to its physiologic ligands is important for the development of normal immune response *in vivo*. Integrin CD11b/CD18 is also a key cellular effector of various inflammatory and autoimmune diseases. However, small molecules selectively inhibiting the function of integrin CD11b/CD18 are currently lacking. We used a newly described cell-based high throughput screening assay to identify a number of highly potent antagonists of integrin CD11b/CD18 from chemical libraries containing >100,000 unique compounds. Computational analyses suggest that the identified compounds cluster into several different chemical classes. A number of the newly identified compounds blocked adhesion of wild-type mouse neutrophils to CD11b/CD18 ligand fibrinogen. Mapping the most active compounds against chemical fingerprints of known antagonists of related integrin CD11a/CD18 shows little structural similarity, suggesting that the newly identified compounds are novel and unique.

Keywords

Integrin; CD11b/CD18; inhibitor; screening; HTS assay; adhesion assay

Introduction

Integrins are heterodimeric receptors composed of non-covalently linked α - and β -chains that mediate cell adhesion, migration and signaling [1]. The β 2 family of integrins has a common β -chain (β 2, CD18) and one of four different α -chains (CD11a, CD11b, CD11c and

© 2010 Elsevier Inc. All rights reserved.

*Correspondence should be addressed to: Vineet Gupta Present Address: Division of Nephrology and Hypertension, Miller School of Medicine, University of Miami, Miami, FL 33136. vgupta2@med.miami.edu; Tel: 305-243-2302; Fax: 305-243-3209. Stephan Schürer Center for Computational Science, University of Miami, Miami, FL 33176. sschurer@med.miami.edu; Tel: 305-243-4842.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CD11d), which together form four distinct receptors. The $\beta 2$ integrin CD11b/CD18 (also known as complement receptor type 3 (CR3), Mac-1 and $\alpha M\beta 2$) is primarily expressed on neutrophils, macrophages and monocytes, is critical for the normal function of these cells and plays an important role in the development of inflammatory response [2;3;4]. Integrin CD11b/CD18 recognizes a wide variety of physiologic ligands, including Fibrinogen (Fg), the complement fragment iC3b and CD54 (ICAM-1). Binding of integrin CD11b/CD18 to its ligands is dependent on divalent cations and is tightly regulated *in vivo*. Integrin CD11b/CD18 is expressed in a low-affinity, inactive conformation in circulating leukocytes, but is rapidly upregulated on cell surface and activated to high-affinity, active conformation on a sub-second timescale [5]. A loss of functional $\beta 2$ integrins in humans leads to leukocyte adhesion deficiency type 1, where circulating neutrophils fail to adhere to or migrate across the endothelium and the patients are susceptible to recurrent, life-threatening bacterial infections [2;3;4]. Conversely, inappropriate excessive activation of leukocyte integrins is also harmful, which contributes to sustained inflammation, ischemia-reperfusion injury [1;2], tissue damage [6], stroke [7], neointimal thickening in response to vascular injury [8] and the development of various autoimmune diseases [9], making it an important therapeutic target [10].

Indeed, blocking antibodies that prevent cell adhesion have been effective in animal models of a number of inflammatory diseases [11;12]. However, the humanized antiintegrin blocking antibodies failed to show much benefit in a number of clinical studies [13]. Additionally, adverse effects due to the nonselective blockade of various other leukocyte functions by mAbs further complicates their use as a therapeutic agent [14]. Similarly, ligand mimics, such as recombinant glycoprotein neutrophil inhibitory factor (NIF) while effective in animals, was clinically ineffective in a phase II trial and was abandoned [15]. Recombinant proteins, such as the ligand-binding A-domain (also known as I-domain) of CD11b that act as competitive antagonists have shown promising results in animals, but have yet to be tested in human studies [16]. Competitive ligandmimetic peptides derived either from CD11b/CD18 ligands or anti-CD11b/CD18 mAbs were reported to be ineffective in blocking ligand binding *in vitro* [17]. Thus, integrin CD11b/CD18 selective small molecules may be more promising therapeutic agents, especially compounds that target allosteric regulatory sites, such as the hydrophobic pocket known as site-for-isoleucine (SILEN) in CD11b/CD18 [18] (termed lovastatin binding site (L-site) [19] or I domain allosteric site (IDAS) [20] in related integrin CD11a/CD18). In fact, several small molecule antagonists targeting IDAS in integrin CD11a/CD18 have been reported (reviewed in [21]). Although a number of integrin CD11a/CD18 antagonists cross-react with integrin CD11b/CD18 and block its function, there are very few reports of antagonists targeting integrin CD11b/CD18 [22], primarily due to the lack of good high-throughput screening (HTS) assays with integrin CD11b/CD18. We recently described a novel cell-adhesion based HTS assay using the 384-well plate format that is ideal for the discovery of small molecule integrin CD11b/CD18 antagonists [23]. In this communication, we describe the discovery of several novel small molecule antagonists of integrin CD11b/CD18 using a modification of this HTS assay. Many of the newly identified compounds show high potency (IC_{50} of $<1\mu M$). The compounds show little structural similarity to known integrin CD11a/CD18 antagonists. Using chemical clustering analyses, we also identified potential lead compounds for development into potential therapeutics in the future.

Materials and Methods

Details of the assay reagents and the HTS assay methods are presented in associated Supplementary Materials.

Activity Scoring and Hit Identification

Cell-adhesion under positive and negative control conditions was used to define the activity scale; signal corresponding to the number of non-small molecule treated cells adherent in activating buffer condition (in the presence of Mn^{2+} ions as agonist, PC) was considered maximum (100% binding) and the signal corresponding to the number of non-small molecule treated cells adherent in basal buffer condition (in the presence of 1mM each of Ca^{2+} and Mg^{2+} , NC) was considered minimum (0% binding). Percent inhibition (or activity) for compounds was calculated on this scale using the following formula (where A represents the measurement from compound treated wells):

$$\% \text{ Inhibition} = \frac{(PC - A)}{(PC - NC)} \times 100$$

Compounds with $\geq 50\%$ inhibition ($\geq 50\%$ activity) of cell adhesion in the primary screen were selected as primary positives. The primary positives were cherry picked and retested in the assay at the same concentration (10 μ M). In the screen with ~92,500 compounds, the primary positives that resulted in $\geq 40\%$ inhibition ($\geq 40\%$ activity) in the confirmatory screen were considered active and were used to generate dose-response curves.

Dose-response data were fitted to the Hill equation and the IC_{50} values (concentration needed for 50% inhibition of cell-adhesion) were calculated with GraphPad Prism (San Diego, CA) with four parameter logistic curve fitting, as previously described [23]. EC_{50} values (concentration needed for half-maximal increase in cell-adhesion) were similarly determined. All data are reported as mean $\pm$ SD. Z'-factor was calculated as previously described [24].

Data Sets and Data Aggregation

The integrin CD11b/CD18 ligand binding antagonist screening data from primary (Pubchem Assay ID (AID) 1497), confirmatory and dose-response assays was aggregated into one dataset. To evaluate cell toxicity we used two additional data sets available in PubChem, one against Jurkat cells (AIDs 364, 463, 464) and the other against HT1018 cells (AID 620). Unique chemical structure representations for the compounds in the aggregated dataset were generated using an in-house Scitegic Pipeline Pilot [25] protocol to remove salt forms (or other addends), generate consistent protonation states (at pH 7.4) and charge representations, standardize stereochemical representations, and canonicalize tautomers. Dose-response data was converted into pIC_{50} values ($-\log_{10}[IC_{50}]$ in Molar concentration unit) and the datasets were subsequently aggregated by averaging exact values of the same measure. Various physicochemical descriptors for compounds were calculated using the Accelrys predictors implemented in Pipeline Pilot.

Compound Clustering

Chemical series corresponding to the most active compounds were generated using Leadscope [26]. Structures of all 63 structurally unique compounds with $pIC_{50} \geq 6$ ($IC_{50} \leq 1\mu$ M) were enriched by adding compounds that are greater than 60% similar using Leadscope keys (and the Tanimoto metric). To remove redundancies and to obtain unique structurally homogeneous classes, the resulting compounds were clustered (via hierarchical agglomerative clustering, average linkage, Leadscope keys) using a cluster height of 0.5. For each cluster the average activity of the antagonist and the cell proliferation results were also calculated. The z-scores for the antagonist HTS assay results is defined as the number of standard deviations that the cluster average is away from the global average of the data set.

Neutrophil adhesion assay

Neutrophils from 8- to 10-week old WT B6 mice were isolated from thioglycollate-stimulated peritonea according to literature protocols [27]. Cells were suspended in TBS containing 0.5% gelatin and transferred to ligand-coated wells. Cells were incubated with 5 μ M antagonists, in the presence of agonists Mn²⁺-ions (0.1mM) or PMA (15nM), for 10 min at 37°C. Subsequently, the assay plates were gently inverted for 30min at room-temperature to dislodge the non-adherent cells. Cells remaining adherent were quantitated using imaging microscopy, as previously described [23;28]. Assays were performed in triplicate wells.

Results and Discussion

HTS Screening of Chemical Libraries Against Integrin CD11b/CD18

We used a cell-based adhesion assay using erythroleukemic K562 cells stably transfected with the wild type integrin CD11b/CD18 (K562 CD11b/CD18) in our screening assays, as previously described [23]. Wild type integrin is expressed in an inactive state in this cell line [29], but can be activated by inside-out signals or by Mn²⁺ ions primarily through a change in integrin affinity rather than avidity [30], thus providing an excellent context for the discovery of small molecule inhibitors of integrins [29]. In the adhesion assay, K562 CD11b/CD18 show minimal adhesion to Fibrinogen (Fg) immobilized on 384-well plates in assay buffer (Tris buffered saline (TBS)) containing physiologic 1mM Ca²⁺ and 1mM Mg²⁺ ions (conditions that maintain integrin in a low-affinity conformation). However, K562 CD11b/CD18 cells show high binding to the immobilized ligand in the presence of agonist Mn²⁺ ions in the assay buffer (conditions that convert integrin into a high-affinity conformation). As shown in Figure 1A, Mn²⁺ ions induce K562 CD11/CD18 cell adhesion to Fg in a dose dependent fashion, with an apparent EC₅₀ value of 65 μ M in this assay, in agreement with literature values with other integrins [31]. Additionally, as shown in Figure 1B, 80%-90% of input cells (as measured by cell adhesion to immobilized anti-CD18 mAb IB4 [32]) showed binding in the presence of agonist Mn²⁺ ions from very low (500 cells) to very high (30,000) number of input cells per well, providing high signal and good dynamic range in the assay. Binding remained minimal at all cell concentrations in the presence of Ca²⁺ and Mg²⁺ ions. Furthermore, incubation with known integrin CD11b/CD18 antagonists, mAbs IB4 and 44a, also blocked the agonist Mn²⁺ ion induced binding to immobilized Fg (Figure 1C), establishing that cell-adhesion is integrin CD11b/CD18 dependent [23].

First, we performed a pilot screen using a commercially available library of >10,500 small molecules to identify novel antagonists of integrin CD11b/CD18 (inhibitors of integrin-dependent cell-adhesion) using this assay. 101 compounds significantly decreased adhesion ($\geq$ 50% inhibition) of K562 CD11b/CD18 cells to immobilized Fg in the presence of agonist Mn²⁺ ions in duplicate wells and were identified as primary positives from this screen (hit-rate of <1%). We cherry-picked the top 37 primary positive compounds that produced the highest level of decrease in Mn²⁺ induced cell-adhesion for validation. We found that 11 of the selected compounds showed more than 50% inhibition of cell-adhesion in the confirmatory assays and were confirmed as antagonists (hit confirmation rate of ~30%). Assays with 5 compounds were inconclusive and the rest of the compounds showed no effect. The selected compounds inhibited K562 CD11b/CD18 adhesion to Fg in a dose dependent fashion, with IC₅₀ values in the low micromolar range [23].

Next, we used this assay to screen a chemical library of approximately 92,500 compounds (part of the NIH Roadmap Initiative small molecule library collection at BCCG as part of MLSCN). The average Z'-factor value for the entire screen was 0.65, and every assay plate

had acceptable Z'-factor values (≥ 0.5). The primary screening data is graphically presented in Figure 2. Results of this assay have been deposited into the Pubchem [33]. In the primary screen, 1658 compounds showed $\geq 50\%$ inhibition of K562 CD11b/CD18 cell-adhesion to immobilized Fg in the presence of agonist Mn^{2+} ions and we identified them as primary positives from this screen (hit-rate of $\sim 1.8\%$). All 1658 compounds were cherry picked from the diluted compound plates used to generate the original primary screening data and retested in the assay. Of the 1658 compounds, 456 reproduced (showed $\geq 40\%$ activity) and were ordered from the NIH small molecule repository (hit confirmation rate of 27.5%). We identified these as secondary positives.

We obtained 394 of the secondary positives from the repository and used them in a dose-response study. Compounds were tested in duplicate at 7-10 different concentrations (2-fold dilution series) to generate the dose-response curves and the IC_{50} values for each compound. Additionally, the majority of the compounds were tested in three independent dose-response assays to determine the IC_{50} values with high confidence. 383 of the 394 secondary positives showed an average IC_{50} value of $< 10 \mu M$ and were confirmed as antagonist hits (97% secondary hit confirmation rate). 63 unique compounds showed sub-micromolar binding ($pIC_{50} \geq 6$, corresponding to $IC_{50} \leq 1 \mu M$), and are shown in Table S2. In comparison, lovastatin a known antagonist of the related integrin CD11a/CD18, is reported to have an IC_{50} of $25 \mu M$ in similar cell-based assays [20].

Compound clustering and identification of enriched structural motifs

In order to analyze the newly identified antagonists we aggregated the primary, confirmatory and dose-response data into a single dataset. Furthermore, we added screening data from additional Pubchem assays, one against Jurkat cells and the other against HT1018 cells, to this dataset in order to evaluate possible cellular toxicity of the identified compounds, as previously described [34]. We generated unique chemical structure representations, as described in the *materials and methods* section, and all resulting data was aggregated by unique structures.

Next, we used cheminformatics application Leadscape to generate activity-enriched clusters of structurally similar compounds [35]. Similarity clusters were built around seed compounds with $IC_{50} \leq 1 \mu M$ followed by hierarchical clustering to remove redundancy and scoring of the unique structurally homogeneous clusters as described in *materials and methods*. Table S1 shows the resulting 45 unique compound series and a group of 17 singletons along with the activity (pIC_{50} value) and potential cytotoxicity for each group. Various physicochemical descriptors (such as surface area and volume, aqueous solubility, partition coefficient between n-octanol and water (cLogP), passive intestinal absorption) were also calculated for the identified antagonists using the predictors from Accelrys (not shown). Although cytotoxicity data are not available for all positive compounds, the presence of toxicity data for one or some compounds in a cluster can be a starting point to evaluate potential toxicity of a class of compounds. For example cluster 1 is among the most active, however at least one compound shows toxicity against Jurkat cells at sub-micromolar concentrations. The same is the case for cluster 2. Although cytotoxicity data is not available for cluster 3, the two trifluoro-methyl groups may make the compounds less soluble (predicted aqueous solubility < 0.1 to $1 \mu M$) and thus not as attractive. Compounds of cluster 6 and 7 also have similar (calculated) properties. Likewise, the highly conjugated aromatic compounds of cluster 4 have low predicted aqueous solubility (< 0.01 to $0.1 \mu M$) and a cLogP of close to 5. Compounds in cluster 38 appear interesting, but show some toxicity in the Jurkat cell assay. However, the sulfonamide compounds present in clusters 11 and 14 show high activity and an acceptable range of predicted physicochemical properties (aqueous solubility, cLogP, polar surface area, passive intestinal absorption). These compounds do not indicate obvious toxicity and their chemical structure suggests that their

analogs could be readily synthesized for future structure-activity studies (SAR). For example, one compound (**1**, Figure 3A, PubchemSID 14720802) in cluster 14 is small, shows good antagonistic activity ($IC_{50} = 0.5 \pm 0.15 \mu M$), is a possible lead-series and a target for further optimization in the future.

To evaluate the novelty of the identified inhibitors, we compared structural similarity of all 383 identified antagonists with $IC_{50} \leq 10 \mu M$ to 11 of the structurally well-defined antagonists of related integrin CD11a/CD18 (see supplementary methods). The results showing all similarity values of chemical fingerprints are in supporting Table S2. A histogram of the highest similarity value of each compound to any of the reference compounds is shown in Figure S1. The results show that none of the 383 compounds have a similarity value >0.4 , suggesting that our identified antagonists are structurally unique and novel. Structural comparison using extended connectivity functional group type fingerprints, instead of the atom type, ECFP4 fingerprints used for Figure S1, yielded similar results. However, structural dissimilarity with known antagonists with a defined mechanism of action also prevents us from identifying potential mechanism of action for the identified antagonists.

Validation of hits using mouse neutrophils

The integrin CD11b/CD18 is primarily expressed on leukocytes. To examine the antagonistic activity of the identified hit compounds in a physiologically relevant cell type, we purchased a number of identified hits [23] (Figure 3A) in a powder form and tested them for their effect on neutrophil cell adhesion. All of the seven selected compounds had shown high antagonistic activity in the HTS assays [23;33]. WT B6 mouse neutrophils did not bind to immobilized CD11b/CD18 ligand fibrinogen (Fg) under physiologic conditions. However, integrin activation using divalent Mn^{2+} ions or PKC agonist phorbol 12-myristate 13-acetate (PMA) lead to dramatic increase in the neutrophil adhesion to Fg (Figure 3B). We find that the novel antagonists potently block agonists Mn^{2+} and PMA-induced adhesion of mouse neutrophils to Fg (Figure 3B).

In conclusion, we have identified a number of highly potent small molecule antagonists of integrin CD11b/CD18. Given that integrin CD11b/CD18 plays a key role in regulating leukocyte function, we believe that the newly identified antagonists will not only provide lead compounds for the development of potential therapeutics, but will also prove to be important new chemical biology tools for the study of the mechanism of integrin activation and function.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Hiba Tannoury, Dr. Jun Y. Park and Dr. Jack Rosa for generous help and discussions with the cell-based assays; Dr. Thomas D. Y. Chung ("TC") and the staff of BCCG and Dr. Caroline Shamu and the staff of ICCB for their generous support in the implementation of the HTS assay and Prof. M. Amin Arnaout for helpful discussions. This work was supported in part by NIH Grants K01DK068253 and R03NS053659 and with resources of the Center for Computational Science at the University of Miami (#164). The MLSCN screening was performed by BTB, ES, MH, SV and ES at Conrad Prebys Center for Chemical Genomics (CPCCG) and was supported through NIH Roadmap grant U54HG003916.

References

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. *Cell*. 2002; 110:673–87. [PubMed: 12297042]
2. Arnaout MA. Leukocyte adhesion molecules deficiency: its structural basis, pathophysiology and implications for modulating the inflammatory response. *Immunol Rev*. 1990; 114:145–80. [PubMed: 1973407]
3. Horwitz AF. Integrins and health. *Sci Am*. 1997; 276:68–75. [PubMed: 9109263]
4. McDowall A, Inwald D, Leitinger B, Jones A, Liesner R, Klein N, Hogg N. A novel form of integrin dysfunction involving beta1, beta2, and beta3 integrins. *J Clin Invest*. 2003; 111:51–60. [PubMed: 12511588]
5. Hogg N, Leitinger B. Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1. *J Leukoc Biol*. 2001; 69:893–8. [PubMed: 11404373]
6. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. *J Biol Chem*. 2000; 275:21785–8. [PubMed: 10801897]
7. Soriano SG, Coxon A, Wang YF, Frosch MP, Lipton SA, Hickey PR, Mayadas TN. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. *Stroke*. 1999; 30:134–9. [PubMed: 9880401]
8. Simon DI, Dhen Z, Seifert P, Edelman ER, Ballantyne CM, Rogers C. Decreased neointimal formation in Mac-1(–/–) mice reveals a role for inflammation in vascular repair after angioplasty. *J Clin Invest*. 2000; 105:293–300. [PubMed: 10675355]
9. Tang T, Rosenkranz A, Assmann KJ, Goodman MJ, Gutierrez-Ramos JC, Carroll MC, Cotran RS, Mayadas TN. A role for Mac-1 (CD11b/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcγ receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. *J Exp Med*. 1997; 186:1853–63. [PubMed: 9382884]
10. Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. *J Leukoc Biol*. 2005; 77:129–40. [PubMed: 15548573]
11. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ, Smith CW. Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. *Hepatology*. 1993; 17:915–23. [PubMed: 8387952]
12. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. *Proc Natl Acad Sci U S A*. 1998; 95:10134–9. [PubMed: 9707613]
13. Dove A. CD18 trials disappoint again. *Nat Biotechnol*. 2000; 18:817–8. [PubMed: 10932141]
14. Ramamoorthy C, Sasaki SS, Su DL, Sharar SR, Harlan JM, Winn RK. CD18 adhesion blockade decreases bacterial clearance and neutrophil recruitment after intrapulmonary *E. coli*, but not after *S. aureus*. *J Leukoc Biol*. 1997; 61:167–72. [PubMed: 9021922]
15. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. *Stroke*. 2003; 34:2543–8. [PubMed: 14563972]
16. Zerria K, Jerbi E, Hammami S, Maaroufi A, Boubaker S, Xiong JP, Arnaout MA, Fathallah DM. Recombinant integrin CD11b A-domain blocks polymorphonuclear cells recruitment and protects against skeletal muscle inflammatory injury in the rat. *Immunology*. 2006; 119:431–40. [PubMed: 17026721]
17. Feng Y, Chung D, Garrard L, McEnroe G, Lim D, Scardina J, McFadden K, Guzzetta A, Lam A, Abraham J, Liu D, Endemann G. Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1. *J Biol Chem*. 1998; 273:5625–30. [PubMed: 9488691]
18. Xiong JP, Li R, Essafi M, Stehle T, Arnaout MA. An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain. *J Biol Chem*. 2000; 275:38762–7. [PubMed: 11034990]
19. Huth JR, Olejniczak ET, Mendoza R, Liang H, Harris EA, Lupher ML Jr, Wilson AE, Fesik SW, Staunton DE. NMR and mutagenesis evidence for an I domain allosteric site that regulates

- lymphocyte function-associated antigen 1 ligand binding. *Proc Natl Acad Sci U S A*. 2000; 97:5231–6. [PubMed: 10805782]
20. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, Cottens S, Weitz-Schmidt G, Hommel U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. *J Mol Biol*. 1999; 292:1–9. [PubMed: 10493852]
21. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. *Nat Rev Drug Discov*. 2003; 2:703–16. [PubMed: 12951577]
22. Bansal VS, Vaidya S, Somers EP, Kanuga M, Shevell D, Weikel R, Detmers PA. Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes. *J Pharmacol Exp Ther*. 2003; 304:1016–24. [PubMed: 12604677]
23. Park JY, Arnaout MA, Gupta V. A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the integrin CD11b/CD18. *J Biomol Screen*. 2007; 12:406–17. [PubMed: 17438069]
24. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen*. 1999; 4:67–73. [PubMed: 10838414]
25. Pipeline Pilot 7.5. Accelrys; San Diego: 2009.
26. Leadscope Enterprise. Leadscope Inc.; Columbus: 2007.
27. Chen LY, Shieh JJ, Lin B, Pan CJ, Gao JL, Murphy PM, Roe TF, Moses S, Ward JM, Lee EJ, Westphal H, Mansfield BC, Chou JY. Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. *Hum Mol Genet*. 2003; 12:2547–58. [PubMed: 12925567]
28. Bergmeier W, Goerge T, Wang HW, Crittenden JR, Baldwin AC, Cifuni SM, Housman DE, Graybiel AM, Wagner DD. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. *J Clin Invest*. 2007; 117:1699–707. [PubMed: 17492052]
29. Ortlepp S, Stephens PE, Hogg N, Figdor CG, Robinson MK. Antibodies that activate beta 2 integrins can generate different ligand binding states. *Eur J Immunol*. 1995; 25:637–43. [PubMed: 7535698]
30. Beals CR, Edwards AC, Gottschalk RJ, Kuijpers TW, Staunton DE. CD18 activation epitopes induced by leukocyte activation. *J Immunol*. 2001; 167:6113–22. [PubMed: 11714770]
31. Masumoto A, Hemler ME. Mutation of putative divalent cation sites in the alpha 4 subunit of the integrin VLA-4: distinct effects on adhesion to CS1/fibronectin, VCAM-1, and invasin. *J Cell Biol*. 1993; 123:245–53. [PubMed: 7691827]
32. Wright SD, Rao PE, Van Voorhis WC, Craigmyle LS, Iida K, Talle MA, Westberg EF, Goldstein G, Silverstein SC. Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. *Proc Natl Acad Sci U S A*. 1983; 80:5699–703. [PubMed: 6225125]
33. Gupta V. HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay. Pubchem Assay ID 1497. 2009
34. Guha R, Schurer SC. Utilizing high throughput screening data for predictive toxicology models: protocols and application to MLSCN assays. *J Comput Aided Mol Des*. 2008; 22:367–84. [PubMed: 18283419]
35. Blower PE Jr, Cross KP, Fligner MA, Myatt GJ, Verducci JS, Yang C. Systematic analysis of large screening sets in drug discovery. *Curr Drug Discov Technol*. 2004; 1:37–47. [PubMed: 16472218]

Figure 1. Characteristics of the cell-adhesion based HTS assay

A. A dose-response curve showing K562 CD11b/CD18 cell-adhesion to immobilized Fg in response to increasing concentration of activating Mn^{2+} ions. Mn^{2+} concentration is along the x-axis (log-scale) and the number of adherent cells (determined using automated microscopy [23]) is along the y-axis. Curve fitting was done using Graphpad Prism and the calculated EC_{50} value is shown. Each point represents a single determination. **B.** A graph showing the number of adherent cells (y-axis) as a function of increasing number of input cells (x-axis) under three different assay conditions- the immobilized antibody IB4 (which captures majority of input K562 CD11b/CD18 cells), 1mM each of Ca^{2+} and Mg^{2+} ions (to determine background levels of cell adhesion under non-activating conditions) and 1mM Mn^{2+} ions (to determine number of cells adherent under activating conditions). Each point represents mean $\pm$ SD of triplicate determinations. **C.** A bar graph showing inhibition of agonist Mn^{2+} induced cell adhesion by blocking mAbs. Cells were incubated in the presence of Mn^{2+} ions (1mM), Ca^{2+} and Mg^{2+} ions (1mM of each) or Mn^{2+} ions (1mM) and blocking mAbs IB4 or 44a for 30min at 37°C in assay wells coated with ligand Fg. Each bar represents mean $\pm$ SD of three to six determinations.

Figure 2.

High throughput screening data for the integrin CD11b/CD18 antagonist assay using a chemical library of ~92,500 compounds. **A.** A graph showing the raw experimental data. Each dot represents % Activity measurement from an assay well. Blue colored dots represent measurements from compound treated wells and red colored dots represent measurements from positive and negative control wells. The graph was prepared using Spotfire software (Sommerville, MA). **B.** A histogram showing a summary of percent inhibition (x-axis) by a number of compounds (y-axis). Percent inhibition was binned into 5% activity intervals. Percent inhibition from positive control and negative control wells is shown as red histogram. Percent activity from tested compounds is shown as blue histograms.

Figure 3. Novel compounds inhibit CD11b/CD18 dependent adhesion of mouse neutrophils. **A.** Chemical structures of identified hit compounds. **B.** A histogram showing adhesion of mouse neutrophils to immobilized Fg in the control physiologic buffer containing 1mM Ca^{2+} and Mg^{2+} (Con), with agonists (Mn^{2+} and PMA), and with agonists in the presence of one of the newly identified antagonists.